Scientific Advisory Board

DOUG FALLER, M.D., PH.D.

Dr. Faller is a Professor of Medicine, Pediatrics, Biochemistry, Microbiology, Pathology and Laboratory Medicine; former Director of the Cancer Center; and former Vice-Chairman, Division of Medicine, of Boston University School of Medicine. He is a hematologist/oncologist, author of hundreds of scientific papers and recipient of numerous grants. He is an acknowledged expert in basic molecular and cellular biology of virus- and oncogene-transformed cells and tumors.

He leads a translational research program which develops molecular cancer therapeutics derived from his basic research, and tests them in clinical trials. He has been the scientific founder of several biotech start-ups including HemaQuest Pharmaceuticals, Phoenicia Biosciences and Viracta Therapeutics.

CARA L. HAYMAKER, PH.D.

Dr. Cara Haymaker is an assistant professor at Department of Translational Molecular Pathology, Division of Pathology/Lab Medicine at The University of Texas MD Anderson Cancer Center. She has been appointed as Director, CCSG Oncology Research and Immunomonitoring Core, Department of Translational Molecular Pathology, Division of Pathology and Lab Medicine since 2018, and as Faculty Member, Translational Molecular Pathology Immunoprofiling Laboratory (TMP-IL) since 2016 at MD Anderson. Dr. Haymaker’s research has focused on Tumor-infiltrating Lymphocytes and their Immunologic Characteristics in solid tumors. Dr. Haymaker earned a Ph.D. in immunology from University of Missouri, Columbia, MO, and has completed her Postdoctoral Fellowship at MD Anderson. She has authored 45 peer-reviewed original research articles.

THOMAS KIEBER-EMMONS, PH.D.

Dr. Kieber-Emmons is known for his work on molecular and structural immunology, developing peptide mimetics of carbohydrate antigens as vaccines in both the cancer and pathogen areas, an acknowledged pioneer in this field. Dr. Kieber-Emmons has both translational and clinical trial experience. Dr. Kieber-Emmons has brought the first carbohydrate mimetic peptide through preclinical development to Phase II Clinical Trials in Breast Cancer and in other cancer indications.
Dr. Kieber-Emmons was recruited from the University of Pennsylvania in 2002 to the University of Arkansas for Medical Sciences where he holds the Jossetta Wilkins Chair in Breast Cancer Research, and is a Director at the Winthrop P. Rockefeller Cancer Institute.

BRIAN METCALF, PH.D.

Dr. Metcalf recently retired as CSO from Global Blood Therapeutics. GBT currently has a Phase III study underway with GBT440 for sickle cell anemia. Earlier he served as head, drug discovery at Incyte Pharmaceuticals. During his tenure at Incyte, the company was transformed from a genomics information company to one focused on drug discovery, culminating in the discovery of Jakafi, a JAK1/2 kinase inhibitor.

Jakafi was approved for the treatment of myelofibrosis by the FDA in 2011. Prior to Incyte, Metcalf was the chief scientific officer of Kosan Biosciences. Prior to that, he served in a number of executive management positions with SmithKline Beecham over the course of 17 years, most recently as worldwide head of discovery chemistry and platform technologies. Dr. Metcalf is credited with the discovery Sabril, for epilepsy and has numerous patents and publications in the drug discovery arena.

MARIA TROJANOWSKA, PH.D

Dr. Trojanowska is a Professor of Medicine and Director of the Arthritis Center at the Boston University School of Medicine. An expert in immunology and fibrotic diseases, her research focuses on the molecular and cellular mechanisms that underlie pathogenic processes responsible for tissue fibrosis and vasculopathy in scleroderma.

ROBERT WILLIAMS, PH.D.

Dr. Williams is a University Distinguished Professor of Chemistry at Colorado State University. He is an innovative scientist who has been instrumental in the development of several biotechnology companies, including Microcide, Xcyte Therapies, HemaQuest, Arch Therapeutics and Cetya Therapeutics. Author of over three-hundred scientific papers, nineteen patents and recipient of numerous research grants, his research interests currently focus on the study of significant problems in synthetic organic chemistry, medicinal chemistry, chemical biology, process chemistry and pharmaceutical drug formulation.

His research program at Colorado State University, is focused on designing, synthesizing and developing small-molecule drugs for the treatment of cancer, autoimmune diseases, multiple drug-resistant bacterial infectious diseases and hemoglobinopathies. His academic lab is focused on the chemistry of natural products and utilizes the tools of organic synthesis to study the biosynthesis, and mechanism of action of numerous families of biomedically relevant natural products. Dr. Williams also has extensive expertise in the chemistry of amino acids, peptides, alkaloids and heterocyclic compounds. Dr. Williams is the recipient of numerous awards and honors including the American Chemical Society Ernest Guenther Award in the Chemistry of Natural Products in 2011, the American Chemical Scoiety Arthur C. Cope Scholars Award in 2002, the Multiple Myeloma Research Foundation Senior Award in 2009 among others.